Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation

Area of Science:

• Clinical pharmacology
• Pediatric neurology
• Drug development

Background:

• Extrapolation of adult data can reduce pediatric clinical trial requirements.
• Current methods for pediatric epilepsy drug development may be inefficient.
• Paediatric epilepsies require tailored therapeutic strategies.

Purpose of the Study:

• To propose a new paradigm for developing drugs for pediatric focal epilepsies.
• To outline the role of data extrapolation in pediatric drug licensing.
• To identify benefits for patients, clinicians, and sponsors.

Main Methods:

• Consensus expert opinion was used to formulate the proposal.
• Phase I trials in adults.
• Simultaneous Phase II and III trials in adults and children over 2 years old.
• Phase IV data collection for neurodevelopmental safety in children.

Main Results:

• A single trial program can support licensing for adjunctive therapy or monotherapy.
• Provisional licensing for children contingent on Phase IV safety data.
• The proposed paradigm aims to reduce costs and expedite access to novel treatments.

Conclusions:

• The proposed paradigm offers a more efficient pathway for pediatric epilepsy drug development.
• This approach benefits all stakeholders by reducing costs and improving treatment access.
• Further consultation with patients, guardians, and regulatory bodies is necessary.